Kilitch Drugs(I)
Kilitch Drugs(I) Performance
Day Range
- Low 349.65
- High 349.65
52 Week Range
- Low 125.00
- High 364.25
- Open Price0.00
- Previous Close356.75
- Volume2407
Start SIP in Kilitch Drugs(I)
Start SIPKilitch Drugs(I) Investment Rating
-
Master Rating:
-
Kilitch Drugs India has an operating revenue of Rs. 153.21 Cr. on a trailing 12-month basis. An annual revenue growth of 22% is outstanding, Pre-tax margin of 9% is okay, ROE of 6% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 18% and 64% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 97 which is a GREAT score indicating consistency in earnings, a RS Rating of 92 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock has great fundamentals and technical strength to stay in momentum.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 32 | 31 | 43 | 29 | 22 | 24 | 32 |
Operating Expenses Qtr Cr | 26 | 26 | 37 | 24 | 19 | 20 | 28 |
Operating Profit Qtr Cr | 6 | 5 | 7 | 4 | 3 | 3 | 4 |
Depreciation Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Qtr Cr | 2 | 1 | 2 | 1 | 0 | 1 | 1 |
Net Profit Qtr Cr | 4 | 4 | 5 | 4 | 4 | 3 | 3 |
Kilitch Drugs(I) Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 15
- Bearish Moving Average
- ___
- 1
- 20 Day
- ₹330.19
- 50 Day
- ₹298.76
- 100 Day
- ₹264.84
- 200 Day
- ₹230.89
- 20 Day
- ₹331.66
- 50 Day
- ₹295.24
- 100 Day
- ₹247.21
- 200 Day
- ₹212.40
Kilitch Drugs(I) Resistance and Support
Resistance | |
---|---|
First Resistance | 349.65 |
Second Resistance | 349.65 |
Third Resistance | 349.65 |
RSI | 74.23 |
MFI | 86.41 |
MACD Single Line | 15.82 |
MACD | 16.49 |
Support | |
---|---|
First Resistance | 349.65 |
Second Resistance | 349.65 |
Third Resistance | 349.65 |
Kilitch Drugs(I) Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 4,175 | 417,500 | 100 |
Week | 14,337 | 1,433,740 | 100 |
1 Month | 16,741 | 1,674,105 | 100 |
6 Month | 14,782 | 1,478,237 | 100 |
Kilitch Drugs(I) Result Highlights
Kilitch Drugs(I) Synopsis
NSE-Medical-Diversified
Kilitch Drugs(I) is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 117.78 Cr. and Equity Capital is Rs. 15.58 Cr. for the Year ended 31/03/2023. Kilitch Drugs(I) Ltd. is a Public Limited Listed company incorporated on 12/05/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1992PLC066718 and registration number is 066718.Market Cap | 562 |
Sales | 134 |
Shares in Float | 0.50 |
No of funds | 1 |
Yield | 0.51 |
Book Value | 2.78 |
U/D Vol ratio | 2.3 |
LTDebt / Equity | |
Alpha | 0.34 |
Beta | 0.6 |
Kilitch Drugs(I)
Owner Name | Sep-23 | Jul-23 | Jun-23 | Mar-23 |
---|---|---|---|---|
Promoters | 69.23% | 69.23% | 68.25% | 68.25% |
Mutual Funds | ||||
Insurance Companies | ||||
Foreign Portfolio Investors | ||||
Financial Institutions/ Banks | ||||
Individual Investors | 26.13% | 26.5% | 27.4% | 27.49% |
Others | 4.64% | 4.27% | 4.35% | 4.26% |
Kilitch Drugs(I) Management
Name | Designation |
---|---|
Mr. Mukund P Mehta | Managing Director |
Mr. Bhavin Mukund Mehta | Whole Time Director |
Mrs. Mira B Mehta | Whole Time Director |
Mr. Hemang Engineer | Independent Director |
Mr. Venkita Subramanian Rajan | Independent Director |
Prof. Vasudev Krishna Murti | Independent Director |
Kilitch Drugs(I) Forecast
Price Estimates
Kilitch Drugs(I) Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-11-09 | Quarterly Results | |
2023-08-11 | Quarterly Results | |
2023-07-22 | Others | To consider and approve conversion of warrants into the equity shares of the Company to the specified person only. per share(5%)Final Dividend |
2023-05-29 | Audited Results | |
2023-02-14 | Quarterly Results |
Kilitch Drugs(I) FAQs
What is Share Price of Kilitch Drugs(I) ?
Kilitch Drugs(I) share price is ₹349 As on 10 December, 2023 | 22:21
What is the Market Cap of Kilitch Drugs(I) ?
The Market Cap of Kilitch Drugs(I) is ₹562.3 Cr As on 10 December, 2023 | 22:21
What is the P/E ratio of Kilitch Drugs(I) ?
The P/E ratio of Kilitch Drugs(I) is 40.1 As on 10 December, 2023 | 22:21
What is the PB ratio of Kilitch Drugs(I) ?
The PB ratio of Kilitch Drugs(I) is 3.7 As on 10 December, 2023 | 22:21